We report the case of a patient who developed extensive brain lesions during fingolimod (FTY720) treatment in the TRANSFORMS study. His initial diagnosis was multiple sclerosis, but after encephalopathy anti-aquaporin4 antibody (anti-AQP4 Ab) was detected, it was changed to neuromyelitis optica spectrum disorder. After treatment with fingolimod, he developed bilateral extensive brain lesions. The brain MRI showed lesions predominantly involving the right frontal and parietal lobes, with vasogenic edema and enhancement. He had residual encephalomalacia and no recurrence with steroid treatment over 3 years following withdrawal of fingolimod.
CohenJABarkhofFComiG. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
2.
WatersPJariusSLittletonE. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol2008; 65: 913–919.
3.
ItoSMoriMMakinoTHayakawaSKuwabaraS. “Cloud-like enhancement” is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol2009; 66: 425–428.
4.
EichelRMeinerZAbramskyOGotkineM. Acute disseminating encephalomyelitis in neuromyelitis optica: closing the floodgates. Arch Neurol2008; 65: 267–271.
ShimizuJHatanakaYHasegawaM. IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology2010; 75: 1423–1427.
7.
BarnettMPrineasJBucklandMParrattJPollardJ. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler2011; in press.
